List of works - Hisao Imai

A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations

scientific article published on 13 October 2018

A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients

scientific article published on 31 July 2017

An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer

scientific article published on 01 May 2019

Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors

scientific article published on 14 August 2018

Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma

scientific article published on 24 October 2019

Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide

scientific article published on 29 June 2016

Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer

scientific article published on August 2016

Clinical significance of post-progression survival in lung cancer

scientific article published on 19 June 2017

Comparison of l-type amino acid transporter 1 expression and l-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer ⬇️

scientific article published on July 24, 2010

Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation

scientific article published on August 1, 2013

Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer

scientific article published on February 1, 2012

Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis

scientific article published on 26 August 2020

Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.

scientific article

Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

scientific article published on 18 December 2019

Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer

scientific article published on 19 March 2020

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer

scientific article published on 06 February 2017

First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations

scientific article published on 8 August 2015

Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment

scientific article published on 03 June 2020

High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma

scientific article published on 26 May 2017

Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study

scientific article published on 24 June 2019

Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer

scientific article published on December 1, 2010

Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study

scientific article published on 27 June 2019

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer ⬇️

scientific article published on September 10, 2012

Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancer ⬇️

scientific article published on August 3, 2011

Patients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer

scientific article published on 02 December 2019

Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

scientific article published on 19 December 2016

Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer

scientific article published on 16 July 2020

Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy

scientific article published on 6 April 2017

Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors

scientific article published on 08 October 2019

Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin

scientific article published on 01 July 2020

Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma

scientific article published on 03 February 2020

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors